STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (MN-33)	SABIRNETUG
PRONUNCIATION	sa bir' ne tug
THERAPEUTIC CLAIM	Treatment of Alzheimer's disease

CHEMICAL NAMES

Immunoglobulin G2 [264-histidine,305-valine,326-alanine,327-proline], anti-(human Aβ oligomer) (human-Mus musculus monoclonal ACU193 g2-chain), disulfide with human-Mus musculus monoclonal ACU193 k-chain, dimer (ACI)

immunoglobulin G2-kappa, anti-[*Homo sapiens* APP (amyloid beta A4 precursor protein) Abeta42 and Abeta40 soluble non-fibrillar oligomers], humanized monoclonal antibody; gamma2 heavy chain humanized (1-443) [VH (*Homo sapiens* IGHV3-48*01 (92.9%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.10] (26-33.51-58.97-106)) (1-117) -*Homo sapiens* IGHG2*01, G2m.. CH2 V45.1 (CH1 (118-215), hinge 1-12 (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-219')-disulfide with kappa light chain humanized (1'-219') [V-KAPPA (*Homo sapiens* IGKV2-28*01 (89.5%) -IGKJ2*03 (100%), CDR-IMGT [11.3.9] (27-37.55-57.94-102)) (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (219-219":220-220":223-223":226-226")-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

STRUCTURAL FORMULA

Heavy Chains: γ2-chain (H, H"):

```
EVQLVESGGG   LVQPGGSLRL   SCAASGFTFS   SFGMHWVRQA   PGKGLEWVAY    50
ISRGSSTIYY   ADTVKGRFTI   SRDNAKNSLY   LQMNSLRAED   TAVYYCARGI   100
TTALDYWGQG   TLVTVSSAST   KGPSVFPLAP   CSRSTSESTA   ALGCLVKDYF   150
PEPVTVSWNS   GALTSGVHTF   PAVLQSSGLY   SLSSVVTVPS   SNFGTQTYTC   200
NVDHKPSNTK   VDKTVERKCC   VECPPCPAPP   VAGPSVFLFP   PKPKDTLMIS   250
RTPEVTCVVV   DVSHEDPEVQ   FNWYVDGVEV   HNAKTKPREE   QFNSTFRVVS   300
VLTVVHQDWL   NGKEYKCKVS   NKGLPAPIEK   TISKTKGQPR   EPQVYTLPPS   350
REEMTKNQVS   LTCLVKGFYP   SDIAVEWESN   GQPENNYKTT   PPMLDSDGSF   400
FLYSKLTVDK   SRWQQGNVFS   CSVMHEALHN   HYTQKSLSLS   PGK          443
```

Light chains: κ-chain (L', L'")

```
DVVMTQSPLS   LPVTPGEPAS   ISCRSSQSIV   HSNGNTYLEW   YLQKPGQSPQ    50'
LLIYKASNRF   SGVPDRFSGS   GSGTDFTLKI   SRVEAEDVGV   YYCFQGSRLG   100'
PSFGQGTKLE   IKRTVAAPSV   FIFPPSDEQL   KSGTASVVCL   LNNFYPREAK   150'
VQWKVDNALQ   SGNSQESVTE   QDSKDSTYSL   SSTLTLSKAD   YEKHKVYACE   200'
VTHQGLSSPV   TKSFNRGEC                                          219'
```

Disulfide bridges: in red, bold text, shaded text indicates interchain (total 18 bridges)

Intra-H(C23-C104)	22-96	144-200	257-317	363-421
	22"-96"	144"-200"	257"-317"	363"-421"
Intra-L(C23-C104)	23'-93'	139'-199'		

	23'''-93'''	**139'''-199'''**		
Inter-H-L(CH1 10-CL 126)	**131-219'**	**131''-219'''**		
Inter-H-H(h 4, h 5, h 6, h 11)	**219-219''**	**220-220''**	**223-223''**	**226-226''**

N-Glycosylation sites: in green bold text

N293 **N293''** (H CH2 N84.4) Predominantly G0F, 99% occupancy; determined

C-terminal lysine clipping: (post translational)

443 443'' (H CHS K2)

CDR-IMGT Regions: **in bold light blue** (protein sequence numbering from above sequence, not IMGT respective sequence numbering)

Heavy Chain CDR1-3 (H, H''):	**26-33 (8)**	**51-58 (8)**	**97-106 (10)**
	26''-33'' (8)	**51''-58'' (8)**	**97''-106'' (10)**
Light Chain CDR1-3 (L', L'''):	**27'-37' (11)**	**55-57' (3)**	**94'-102' (9)**
	27'''-37''' (11)	**55'''-57''' (3)**	**94'''-102''' (9)**

MOLECULAR FORMULA	$C_{6416}H_{9922}N_{1722}O_{2000}S_{50}$ (unglycosylated)
MOLECULAR WEIGHT	144.8 kDa (unglycosylated)
TRADEMARK	None as yet
SPONSOR	Acumen Pharmaceuticals, Inc.
CODE DESIGNATIONS	ACU193
CAS REGISTRY NUMBER	2747959-38-0
UNII	2U1A25MKP9
WHO NUMBER	12509

gbk